Sure it can supplement . The issue is the primary evidence which it supplements which is a RCT phase 3. If everything was so clear cut with this guidance from 2023 according to you , then why didn’t they apply to FDA first
And no read ATL’s post . He didn’t imply that he was talking about compassionate use when referring to his highlighted excerpt from FDA guidance for non interventional studies . He has been posting this in relation to DcVax trial data
Market Data 
Markets 
AI
